FENC Fennec Pharmaceuticals Inc

Price (delayed)

$9.2

Market cap

$319.58M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.28

Enterprise value

$279.4M

?
Relative Growth: Rel. Growth: 93
Relative Strength: Rel. Strength: 65
Relative Valuation: Rel. Valuation: 12
Relative Profitability: Rel. Profitability: 41

Fennec Pharmaceuticals Inc. is a specialty pharmaceutical company focused on the development of PEDMARK™ for the prevention of platinum-induced ototoxicity in pediatric patients. Further, PEDMARK has received Orphan Drug Designation ...

Highlights
FENC's debt has dropped by 100% year-on-year
The gross profit has soared by 69% YoY and by 15% from the previous quarter

Key stats

What are the main financial stats of FENC

FENC stock price

How has the Fennec Pharmaceuticals stock price performed over time
Intraday
0.66%
1 week
-6.98%
1 month
38.35%
1 year
19.87%
YTD
19.48%
QTD
49.59%

Financial performance

How have Fennec Pharmaceuticals's revenue and profit performed over time
Revenue
$51M
Gross profit
$47.04M
Operating income
-$5.59M
Net income
-$8.38M
Gross margin
92.2%
Net margin
-16.4%
Fennec Pharmaceuticals's operating margin has soared by 72% YoY and by 22% from the previous quarter
The gross profit has soared by 69% YoY and by 15% from the previous quarter
FENC's net margin has surged by 65% year-on-year and by 25% since the previous quarter
FENC's revenue has soared by 65% YoY and by 14% from the previous quarter

Price vs fundamentals

How does FENC's price correlate with its fundamentals

Growth

What is Fennec Pharmaceuticals's growth rate over time

Valuation

What is Fennec Pharmaceuticals stock price valuation
P/E
N/A
P/B
8.42
P/S
6.19
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
5.48
The company's EPS rose by 47% YoY and by 18% QoQ
The equity has grown by 6% from the previous quarter
The P/S is 97% lower than the 5-year quarterly average of 181.2 but 8% higher than the last 4 quarters average of 5.7
FENC's revenue has soared by 65% YoY and by 14% from the previous quarter

Efficiency

How efficient is Fennec Pharmaceuticals business performance
The ROE has soared by 75% from the previous quarter
The company's return on sales has surged by 61% YoY and by 21% QoQ
The return on assets has increased by 48% year-on-year and by 23% since the previous quarter
The return on invested capital rose by 19% year-on-year

Dividends

What is FENC's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for FENC.

Financial health

How did Fennec Pharmaceuticals financials performed over time
The total assets is 110% more than the total liabilities
The total assets has soared by 55% YoY
FENC's current ratio is up by 36% year-on-year and by 10% since the previous quarter
FENC's debt is 100% smaller than its equity
The company's debt to equity has surged by 100% YoY
FENC's debt has dropped by 100% year-on-year

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.